An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A group of doctors and researchers from around the world got together to make recommendations about using GLP‑1 receptor agonists (GLP‑1 RAs) during pregnancy. These are drugs many people take for diabetes or weight loss, and the experts wanted to summarize what is known and give guidance because pregnancy raises special concerns. The statement isn’t a new experiment — it’s a review and agreement by specialists, not a randomized clinical trial. GLP‑1 receptor agonists are medicines that act like a natural hormone called GLP‑1, which helps control blood sugar and can reduce appetite. You’ve probably heard of semaglutide — that’s one of them and is the active ingredient in Ozempic and Wegovy. These drugs change how quickly the stomach empties and send signals to the brain that reduce hunger. They’re useful for treating type 2 diabetes and for weight loss, but they haven’t been extensively studied in pregnant people. The international consensus examines existing studies, case reports, and registries to say what is and isn’t known about using these drugs in pregnancy. The evidence is limited. Most data come from a small number of pregnancies that happened before people knew they were pregnant, animal studies, and some registry reports. The experts generally note potential concerns—for example, developmental effects seen in some animal studies and uncertain effects on the baby’s growth—but they also point out that clear, large-scale human data are missing. The consensus therefore tends toward caution rather than endorsement. Why this matters: many people of childbearing age use GLP‑1 drugs for diabetes or weight loss. If someone becomes pregnant or is trying to conceive, they and their clinicians need practical advice. The consensus helps doctors weigh risks and benefits and gives a starting point for counseling patients. It also signals to researchers and regulators where better data are needed so future guidance can be firmer. There are important caveats. Because the human data are sparse, experts often recommend stopping GLP‑1 RAs before conception or as soon as pregnancy is known, especially when the drug was started for weight loss rather than for serious diabetes control. Stopping these drugs can cause blood-sugar or weight changes, so any change should be managed with a clinician. Side effects for the parent can include nausea and digestive symptoms; potential risks to the fetus are not well established. Finally, this is consensus guidance — it summarizes opinions based on current limited evidence — and regulatory decisions and local medical advice may differ. Bottom line: international experts advise caution with GLP‑1 drugs around pregnancy because human data are limited; talk with your clinician about stopping or switching medications if you are planning pregnancy or become pregnant.
Source: Medscape